9 Facts About Using HRT When You Have Migraine With Aura — and Why the Risk Conversation Is More Nuanced Than You Have Been Told
Being handed a flat 'no' on HRT because of aura migraines — without any explanation of why, or whether there were alternatives — is one of the most common stories that lands in this community. The frustration is completely valid. A one-line answer to a complicated question isn't informed consent; it's a shortcut, and women with aura migraines deserve better than that.
Learn more about Rose →Migraine with aura does increase baseline stroke risk — but the absolute numbers matter enormously
Migraine with aura is associated with approximately a twofold increase in ischemic stroke risk compared to people without migraine, which sounds alarming until you look at the absolute numbers: in women under 45 who don't smoke and have no other cardiovascular risk factors, that still translates to a very small absolute risk. Risk conversations that skip from relative risk to 'never use hormones' are leaving out the part of the equation that most shapes clinical decision-making. Understanding a person's individual baseline — age, smoking status, blood pressure, cardiovascular history — is what actually determines whether adding estrogen is a meaningful concern.
Oral estrogen raises clotting factors in a way that transdermal estrogen does not
When estrogen is taken orally, it passes through the liver in high concentrations before entering systemic circulation — a process called first-pass metabolism — which increases the production of clotting factors and raises the risk of venous thromboembolism and, to a lesser extent, arterial events like stroke. Transdermal estrogen (patches, gels, sprays) bypasses the liver entirely, delivering estrogen directly into the bloodstream at much lower concentrations, and multiple studies show it does not carry the same prothrombotic effect. This pharmacological distinction is not a minor footnote; it is central to why route of delivery changes the risk calculation for women with aura migraines significantly.
The stroke risk concern attached to combined oral contraceptives does not translate directly to HRT
Much of the caution around estrogen and stroke in women with aura originated from research on combined oral contraceptives, which use synthetic estrogens at doses many times higher than those used in HRT, alongside synthetic progestogens with their own vascular effects. HRT — particularly low-dose transdermal estradiol — operates on an entirely different hormonal and pharmacological basis. Conflating the two is a common source of confusion in clinical settings, and it has led to women being denied HRT based on evidence that was never derived from HRT populations.
Estrogen fluctuation — not estrogen itself — is one of the primary migraine triggers in perimenopause
The sharp, unpredictable drops in estrogen that define perimenopause are strongly linked to an increase in migraine frequency, because estrogen withdrawal lowers the threshold for cortical spreading depression, the neurological phenomenon that underlies aura. Stabilising estrogen levels through low-dose transdermal therapy can actually reduce the hormonal volatility that was driving more frequent attacks, and some women with aura migraines report improvement rather than worsening when they begin HRT. This does not mean HRT is universally migraine-protective, but it does mean the relationship between estrogen and migraine is bidirectional and context-dependent.
The type of progestogen used alongside estrogen also carries distinct vascular profiles
In women who have a uterus, estrogen must be accompanied by a progestogen to protect the uterine lining, and not all progestogens behave the same way in the vasculature. Synthetic progestogens (progestins) — particularly older norethisterone-based compounds — have androgenic and glucocorticoid activity that can negatively influence lipid profiles and clotting, while micronised progesterone (body-identical progesterone) appears to have a more neutral or even favourable vascular profile. For women with aura migraines, choosing micronised progesterone over a synthetic progestogen is a clinically meaningful preference, not just a personal one.
Current UK and international guidelines do not classify migraine with aura as an absolute contraindication to HRT
The NICE menopause guideline (NG23, updated 2024) and the British Menopause Society both acknowledge that while migraine with aura warrants careful consideration, it is not listed as an absolute contraindication to HRT in the way that it is for combined oral contraceptives. The guidance positions this as a decision requiring individual risk-benefit assessment rather than a categorical exclusion. Women who have been told a flat 'no' by their clinician without any discussion of route, dose, or their personal cardiovascular risk profile have not received the full clinical picture that current guidelines actually support.
Aura frequency and pattern may shift during perimenopause independent of any HRT use
Perimenopause itself alters migraine patterns — some women experience more frequent aura episodes as oestrogen levels become erratic, while others find their migraines change character or timing. This means that any changes in aura after starting HRT need to be interpreted in the context of what perimenopausal hormonal chaos was already doing to migraine patterns, rather than automatically attributed to the HRT. Keeping a detailed migraine diary before and after starting HRT is one of the most practical tools for distinguishing between hormonal background noise and a genuine treatment effect.
Smoking dramatically amplifies stroke risk in women with aura — and is a more powerful modifier than HRT use
The combination of migraine with aura and cigarette smoking creates a synergistic increase in ischemic stroke risk that is substantially larger than either factor alone, and that risk is further compounded by oral estrogen-containing contraceptives. In risk stratification conversations, current smoking status should be weighted heavily — arguably more heavily than the question of whether to use low-dose transdermal HRT. Women with aura who smoke are advised to address smoking cessation as the highest-priority intervention, while the HRT conversation becomes considerably less fraught for non-smokers with no other vascular risk factors.
Any new, prolonged, or unusual aura after starting HRT warrants prompt clinical review
While the evidence supports that low-dose transdermal HRT is a reasonable option for many women with a history of aura migraines, it is equally important that women know what to watch for: a new type of aura, an aura that lasts longer than an hour, aura without headache appearing for the first time, or any neurological symptoms that feel different from their usual pattern. These presentations should prompt immediate contact with a clinician, not because HRT has necessarily caused harm, but because unusual neurological symptoms always warrant evaluation on their own clinical merits. Informed use of HRT means knowing both the reassuring evidence and the signals that require attention.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.